Effect of Impaired Renal Function and Haemodialysis on the Pharmacokinetics of Aprepitant

This publication has 17 references indexed in Scilit:

• Pharmacokinetics of Rosiglitazone in Patients with Varying Degrees of Renal Insufficiency
  The Journal of Clinical Pharmacology, 2003
• The pharmacokinetics of cerivastatin in patients on chronic hemodialysis.
  Int. Journal of Clinical Pharmacology and Therapeutics, 2001
• Prevention of Cisplatin-Induced Emesis by the Oral Neurokinin-1 Antagonist, MK-869, in Combination With Granisetron and Dexamethasone or With Dexamethasone Alone
  Journal of Clinical Oncology, 2001
• Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs
  Int. Journal of Clinical Pharmacology and Therapeutics, 2000
• The novel NK1 receptor antagonist MK–0869 (L–754,030) and its water soluble phosphoryl prodrug, L–758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets
  Neuropharmacology, 2000
• Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist
  New England Journal of Medicine, 1999
• Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment.
  The Journal of Clinical Pharmacology, 1998
• Disease-Induced Variations in Plasma Protein Levels
  Clinical Pharmacokinetics, 1990
• Cyclosporin: measurement of fraction unbound in plasma
  Journal of Pharmacy and Pharmacology, 1987
• Consequences of renal insufficiency on the hepatic clearance of some drugs.
  1983